Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Exclusion Criteria

• •History of thymic pathology (thymoma), thymectomy, or myasthenia gravis.
• •Breast-feeding.
• •Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances.
• •Previous flavivirus vaccination, e.g. Japanese encephalitis or yellow fever.
• •Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures.
• •Planned participation in another clinical trial during the present trial period.
• •History of flavivirus infection (confirmed either clinically, serologically or microbiologically).
• •Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding six months, or long-term systemic corticosteroids therapy.
• •Chronic illness at a stage that could interfere with trial conduct or completion.
• •Blood or blood-derived products received in the past three months.
• •Vaccination planned in the four weeks following the trial vaccination.
• •Flavivirus vaccination planned during the present trial period.
• •Planned travel during the present trial period to areas with high dengue endemicity.
• •Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalised without his/her consent.
• •Participation in another clinical trial in the four weeks preceding the trial vaccination.
• •Any vaccination in the four weeks preceding the trial vaccination.
• •Human Immunodeficiency Virus (HIV), Hepatitis B (Ag HBs) or Hepatitis C (HC) seropositivity in blood sample taken at screening.
• •Laboratory abnormalities considered clinically significant upon the Investigator's judgement in blood sample taken at screening.
• •Positive flavivirus serological test in blood sample taken at screening (for Controls only).